-Medivir said it has agreed to buy two clinical-stage cancer candidates and their related development programs from Tetralogic Pharmaceuticals for up to $238 million in an acquisition the buyer said will enhance its oncology pipeline.
-Medivir said it plans to launch a Phase III trial in the second half of next year (2017) for remetinostat, a topical HDAC inhibitor that the company said is strongly linked to its existing expertise in protease inhibition. Remetinostat is now under study in a late Phase II program designed to treat early-stage cutaneous T-cell lymphoma (CTCL)—a potential market that Medivir said has been estimated at approximately $900 million a year.
-Medivir has agreed to pay Tetralogic $12 million upfront, up to $20 million tied to remetinostat achieving development milestones through regulatory filings; up to $45 million tied to remetinostat winning regulatory approval milestones; and up to $31 million tied to achieving additional commercialization milestones, primarily related to sales. Medivir has also agreed to pay tiered royalties capped at an aggregate of 13% on remetinostat sales.
See the company power powerpoint here, pages 7-12:
It looks like Phase 2 was completed, and they have met with the FDA and will be announcing Phase 3 starting very soon. That could mean about $20-$65 million in milestones coming TLOG's way.
26 million shares Outstanding @ $0.02 = Only a $520,000 market cap.
All my math says this will be a $1+ stock based just on early milestones coming yet this year. Huge upside imo.